Why BioMarin Pharmaceutical Stock Topped the Market on Tuesday
Key Points
The biotech published its latest set of quarterly results.
It posted a surprise net profit for the period.
- 10 stocks we like better than BioMarin Pharmaceutical ›
BioMarin Pharmaceutical (NASDAQ: BMRN) reported its third-quarter earnings after market close Monday, and they were good enough to push the biotech stock almost 2% higher the following day. With that performance, the shares notched a slight beat on the bellwether S&P 500 index, which ticked up by 1.2%.
Surprise, surprise
For the quarter, BioMarin's revenue came in at $776 million, which was 4% higher on a year-over-year basis. Net income not according to generally accepted accounting principles (GAAP), on the other hand, dived sharply by 88% to $22 million, or $0.12 per share.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
Image source: Getty Images.
Despite the steep bottom-line drop, analysts tracking BioMarin stock were expecting worse. Their consensus estimate was for a non-GAAP (adjusted) net loss of $0.12 per share. The company missed on revenue, however, as those pundits were collectively expecting just over $782 million for the metric.
In the earnings release, the company also announced a strategic decision to consider divesting one of its products, Roctavian, which treats severe hemophilia A. It said this "is consistent with BioMarin's portfolio strategy and offers the most promising opportunity for ensuring continued patient access" to the drug.
A raise and a reduction
BioMarin also revised its guidance for full-year 2025. It raised the low end of its range for revenue; now it anticipates this will land at $3.15 billion to $3.2 billion (previously, it was modeling less than $3.13 billion to $3.2 billion). It reduced its projection for adjusted, per-share net income to $3.50 to $3.60. Formerly, this forecast was $4.40 to $4.55.
Should you invest $1,000 in BioMarin Pharmaceutical right now?
Before you buy stock in BioMarin Pharmaceutical, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and BioMarin Pharmaceutical wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $590,287!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,173,807!*
Now, it’s worth noting Stock Advisor’s total average return is 1,047% — a market-crushing outperformance compared to 195% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of October 27, 2025
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends BioMarin Pharmaceutical. The Motley Fool has a disclosure policy.
Recommended Articles
